focus -WSS

focus

author：entertainment 2025-10-04 10:21:07 Page View：42193

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Neuroscience’s long legacy of racism
Next article： Medicare proposal to cover medical devices draws a mixed reaction

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Editas, Vertex strike deal on CRISPR

AdobeForadecade,leadingacademicinstitutesandtheirassociatedcompaniesfoughtabruising,headline-grabbin

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Why health care costs have stayed mostly flat since 2010

AdobeAllAmericansareworriedaboutinflation.Thepricesforhousing,clothesandfoodatthesupermarketareeyepo

focus

explore

leisure time

Why health care costs have stayed mostly flat since 2010